Table 1 Demographics of patients with colorectal cancer or normal colon (clinical specimens used in this study)

From: SPARC promoter hypermethylation in colorectal cancers can be reversed by 5-Aza-2′deoxycytidine to increase SPARC expression and improve therapy response

AJCC staging (colorectal cancer)

Subject age range (mean)

Gender (M/F)

I

44–81 (64)

2/1

II

66–76 (71)

3/1

III

75 (75)

1/0

IV

55–58 (56.5)

2/0

Normal colon

34–68 (54.2)

3/2

Back to article page